The Teva Pharmaceutical Industries Limited (TEVA) shares are trading at lower $11.42 and the avg recommendation for the stock is Moderate Buy. while the current analyst price target stands at $11.59.
To add more color to this target, the company’s high over the last year is $13.76 and the low is $6.07. Over the last 52 weeks, TEVA is down -17.01% while the S&P 500 is down -0.63%. The catalyst for this interesting swing was the company’s recent earnings report.
A Notable Earnings Report
In the last quarter, TEVA reported a profit of $2.06 billion. Teva Pharmaceutical Industries Limited also saw revenues increase to $4.36 billion. In addition, TEVA has free cash flow of $177.0 million as of 03-2020. The company’s EBITDA came in at $1.24 billion which compares well with its peers.
TEVA booked profit margins of -4.90%, its Return on Equity (ROE) is -6.00%, and its Return on Assets is -1.40%. All told, it is clear that, TEVA needs to be on your watchlist.
Find out when TEVA reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. TEVA has a short ratio of 2.10 and outstanding shares of 1.09B.
TEVA has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 5.84 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -0.76. Teva Pharmaceutical Industries Limited TEVA also noted assets of $55.33 billion at the end of the last quarter. Investors should also keep an eye on sector updates as TEVA has historically followed its peers on positive news.
All told, Teva Pharmaceutical Industries Limited TEVA has strung together solid data and demonstrated underlying fundamentals. At its current valuation, TEVA represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Teva Pharmaceutical Industries Limited TEVA is now commanding a market cap of 12.94B and a float of 1.08B. TEVA is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of TEVA stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in TEVA, either long or short, and we have not been compensated for this article.